Hormonal Health

Pancragen

Pancragen (Lys-Glu-Asp-Trp)

Khavinson tetrapeptide for pancreatic function

Pancragen is a synthetic tetrapeptide bioregulator from the Khavinson group designed to support pancreatic function, particularly beta-cell health and insulin regulation.

Pan
💉

Admin routes

Oral (capsule)

🔬

Popularity

Niche

Side effects

Generally mild

🏪

AU vendors

0 rated

Key benefits

1Supports pancreatic beta-cell function (Russian clinical data)
2Oral capsule formulation
3Used alongside standard diabetes management in Russian practice

📈What to expect

1
Day 10-20

Possible improvement in blood glucose regulation (Russian reports)

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Metabolic support (Russian protocol)

Dose

10 mg (1-2 capsules)

Frequency

1-2 times daily

Duration

10-20 day courses, 2-3 times per year

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|Used in Russian clinical practice; limited Western peer review

Overview

Pancragen is a tetrapeptide (Lys-Glu-Asp-Trp) developed at the Saint Petersburg Institute of Bioregulation as a pancreatic tissue bioregulator. It is intended to normalise pancreatic function, particularly insulin production by beta cells. In Russian clinical data, it has been studied in patients with type 2 diabetes and metabolic syndrome. As with all Khavinson bioregulators, the evidence base is primarily Russian clinical studies, and the proposed mechanism of direct DNA interaction remains controversial in Western pharmacology.

⚙️How it works

According to Khavinson's theory, pancragen interacts with DNA regulatory regions in pancreatic beta cells, normalising gene expression related to insulin synthesis and secretion. It is proposed to restore age-declined beta-cell function rather than stimulating additional insulin release.

Side effects

Generally well-tolerated in Russian clinical use
mildRare

📅Research history

2000s

Pancragen developed at the Saint Petersburg Institute of Bioregulation

References

  1. [1]Khavinson VK. 'Peptide bioregulators: a new class of geroprotectors.' 2006.

Frequently asked questions

Related peptides

Community experiences

Share your experience with Pancragen. Effects, side effects, protocol details - help others make informed decisions.

Write a review

Rating:

No community reviews yet. Be the first to share your experience with Pancragen.

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for Pancragen.

Open Calculator

Found this useful?

Share this guide

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.